Direct answer: The latest widely reported development is Helena Teede announcing a name change for PCOS to reflect a broader, multi-system condition, with terms like polyendocrine metabolic ovarian syndrome (PMOS) being used in some coverage and Lancet publication notes. Reports indicate the announcement occurred in May 2026 and was tied to a 14-year international effort.
Details and context:
- What changed: The PCOS label is being updated to better reflect metabolic and endocrine involvement beyond the ovaries, moving away from the implication that the ovaries themselves are inherently “polycystic.” The new nomenclature is intended to improve recognition of reproductive, metabolic, cardiovascular, and psychological risks and to reduce stigma associated with the old term. This reshapes language used in guidelines and patient materials, not the underlying diagnostic criteria or treatment approaches.[1][4]
- Publication and reach: The renaming and accompanying guidelines were highlighted in Lancet and covered by international outlets, signaling formal publication and broad professional uptake.[2][4][1]
- Patient and clinician impact: The shift aims to reduce misperceptions about cysts and to emphasize the condition’s systemic nature, potentially accelerating diagnosis and holistic management for the millions affected worldwide.[1][2]
Concise timeline:
- 2024–2025: International PCOS guidelines and context around terminology discussed publicly, including Teede’s work on naming and guidelines updates.[3][4]
- 2026: Reports indicate official announcement of the name change to PMOS and related guidelines, with Lancet publishing the terminology shift and expanded guidelines.[2][1]
If you want, I can pull up the Lancet article or major news pieces and summarize the exact wording of the terminology change, as well as how current diagnostic criteria and management recommendations align with PMOS. I can also help you locate patient-facing materials or translation-ready resources reflecting the new term.
Sources
guideline for the assessment and management of polycystic ovary syndrome 2023 … Publication approval The guideline recommendations on pages 21 to 49 of this document were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 27 July 2023 under section 14A of the National Health and Medical Research Council Act 1992. In approving the guideline … Updated, expanded and international current version February 2023 Authorship Helena Teede, Chau Thien...
pcoschallenge.orgPodcast Episode · The Fertility Podcast · 15 January 2024 · 46min
podcasts.apple.comUnderstanding polycystic ovary syndrome (PCOS) - Professor Teede is the Director of Monash Centre for Health Research Implementation, Monash University. and an Endocrinologist at Monash Health, who holds an Order of Australia for services to Women’s Health.
joyceharper.compmos is the new name for polycystic ovary syndrome after a 14-year global consultation led by Helena Teede. The change, published in the Lancet and announced in Prague on Tuesday, is meant to replace a label that has confused patients and doctors for decades.For people who have been told they have P…
www.el-balad.comHelena is here to talk about the new PCOS guidelines and the name change. We talked about her diagnosis and the complexity of it.
www.thefertilitypodcast.comPolycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome after 14 years of global collaboration. Helena Teede announced the change in Prague on Tuesday, and the new name was published in the Lancet.The condition affects one in eight women and is estimated to impact 170 mil…
www.el-balad.comTwo of members of the team at Monash Health have been recognised this week in the Queen’s Birthday 2021 Honours List. Both Professor Helena Teede and Professor Beverley Vollenhoven received the Member of the Order of Australia (AM) award. Monash Health extends its congratulations to Helena and Beverley for these well-deserved honours.
monashhealth.org